tirzepatide press release CagriSema 2.4 mg/7.2 mg produced 23% weight loss in an open-label head-to-head trial with tirzepatide. CagriSema was inferior to the 25.5% weight loss with after 84 weeks. https://t.co/d8LjO22N7j FDA Approves Lilly's Zepbound™ (tirzepatide)

Drink Water and Sleep Well Water improves the digestive benefits of GLP-1 and removes waste from your body

Youve probably heard about this benefit, as its a major reason why this wellness option has become so trendy

Reverse bias behavior of halide perovskite solar cells

Hydroxyzine tablets and capsules can appear in different colors, shapes, and imprint codes depending on the manufacturer

Important limitations of the current evidence include: Most trials have been relatively small and of short duration (typically 816 weeks) Study quality varies, with some trials lacking robust blinding or having high dropout rates Publication bias may exist, with negative studies less likely to be published Long-term safety and efficacy data beyond three months are scarce Few studies have been conducted in Western populations or UK healthcare settings The National Institute for Health and Care Excellence (NICE) does not include berberine in its guidelines for diabetes management (NG28), reflecting the lack of sufficient high-quality evidence to support its routine use

April 21, 2025: Kentucky doctor pleads guilty after injecting patients with semaglutide from unregistered sources Major Stories A Kentucky doctor treated weight loss patients with research chemicals